Do analysts prefer NRSN or THAR?

NeuroSense Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 1,727.17%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, NRSN or THAR?

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is NRSN or THAR more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Tharimmune N/A -588.45% -264.41%

Is NRSN or GANX more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Gain Therapeutics N/A -201.44% -136.24%

Is NRSN or FRMM more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Forum Markets N/A -242.09% -135.46%

Does the media favor NRSN or FRMM?

In the previous week, Forum Markets had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 4 mentions for Forum Markets and 2 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.76 beat Forum Markets' score of 0.60 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRSN or ATRA?

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.78 beat NeuroSense Therapeutics' score of 0.76 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer NRSN or SPRO?

NeuroSense Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 1,727.17%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer NRSN or SPRO?

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.84 beat NeuroSense Therapeutics' score of 0.76 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeuroSense Therapeutics (NRSN) Competitors

$0.47 -0.01 (-2.27%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.43 -0.04 (-7.57%)

As of 07/31/2026 07:59 PM Eastern

Compare

NRSN vs. THAR, GANX, FRMM, ATRA, and SPRO

Should you buy NeuroSense Therapeutics stock or one of its competitors? MarketBeat compares NeuroSense Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroSense Therapeutics include Tharimmune (THAR), Gain Therapeutics (GANX), Forum Markets (FRMM), Atara Biotherapeutics (ATRA), and Spero Therapeutics (SPRO).

How does NeuroSense Therapeutics compare to Tharimmune?

NeuroSense Therapeutics (NASDAQ:NRSN) and Tharimmune (NASDAQ:THAR) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

NeuroSense Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 0 mentions for Tharimmune. NeuroSense Therapeutics' average media sentiment score of 0.76 beat Tharimmune's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Positive
Tharimmune	Neutral

NeuroSense Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 1,727.17%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroSense Therapeutics' return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Tharimmune	N/A	-588.45%	-264.41%

Summary

NeuroSense Therapeutics beats Tharimmune on 12 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Gain Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

NeuroSense Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NeuroSense Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 1,727.17%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 346.43%. Given NeuroSense Therapeutics' higher possible upside, equities analysts clearly believe NeuroSense Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 0 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.91 beat NeuroSense Therapeutics' score of 0.76 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroSense Therapeutics	Positive
Gain Therapeutics	Very Positive

NeuroSense Therapeutics has higher earnings, but lower revenue than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Gain Therapeutics	$50K	1,433.04	-$20.16M	-$0.58	N/A

NeuroSense Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Gain Therapeutics	N/A	-201.44%	-136.24%

Summary

NeuroSense Therapeutics beats Gain Therapeutics on 10 of the 15 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Forum Markets?

NeuroSense Therapeutics (NASDAQ:NRSN) and Forum Markets (NASDAQ:FRMM) are related small-cap companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 25.2% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Forum Markets had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 4 mentions for Forum Markets and 2 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.76 beat Forum Markets' score of 0.60 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

NeuroSense Therapeutics' return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Forum Markets	N/A	-242.09%	-135.46%

NeuroSense Therapeutics has higher earnings, but lower revenue than Forum Markets. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Forum Markets	$6.55M	10.55	-$450.52M	-$36.07	N/A

NeuroSense Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 1,727.17%. Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 93.80%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe NeuroSense Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

NeuroSense Therapeutics beats Forum Markets on 10 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Atara Biotherapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.78 beat NeuroSense Therapeutics' score of 0.76 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Atara Biotherapeutics has higher revenue and earnings than NeuroSense Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Atara Biotherapeutics	$23.14M	3.26	$32.69M	-$0.67	N/A

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeuroSense Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. NeuroSense Therapeutics' return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

NeuroSense Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

NeuroSense Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 1,727.17%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 13.37%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NeuroSense Therapeutics beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Spero Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Spero Therapeutics	$66.80M	1.01	$8.57M	$0.24	4.88

Spero Therapeutics has a net margin of 24.90% compared to NeuroSense Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat NeuroSense Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Spero Therapeutics	24.90%	35.58%	24.95%

NeuroSense Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.84 beat NeuroSense Therapeutics' score of 0.76 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 1,727.17%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Spero Therapeutics beats NeuroSense Therapeutics on 9 of the 16 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.50M	$3.61B	$7.22B	$12.30B
Dividend Yield	N/A	3.78%	2.59%	9.45%
P/E Ratio	-0.86	7.71	280.89	24.67
Price / Sales	N/A	1,260.84	586.86	89.25
Price / Cash	N/A	93.43	71.02	59.62
Price / Book	-9.30	16.81	11.07	5.90
Net Income	-$11.12M	-$12.44M	$3.49B	$336.16M
7 Day Performance	-22.74%	-1.42%	-0.24%	0.10%
1 Month Performance	-35.66%	-7.52%	-2.98%	-5.65%
1 Year Performance	-56.93%	48.83%	61.99%	18.86%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	3.4931 of 5 stars	$0.47 -2.3%	$8.50 +1,727.2%	-74.2%	$15.50M	N/A	N/A	10	News Coverage Analyst Downgrade High Trading Volume
THAR Tharimmune	N/A	$2.03 +4.6%	N/A	+48.1%	$76.59M	N/A	N/A	2	Positive News
GANX Gain Therapeutics	3.0139 of 5 stars	$1.74 -6.7%	$7.50 +332.3%	+15.1%	$74.01M	N/A	N/A	20	Positive News
FRMM Forum Markets	3.7358 of 5 stars	$5.29 -4.5%	$10.00 +88.9%	N/A	$71.28M	$6.55M	N/A	7	Insider Trade
ATRA Atara Biotherapeutics	1.8116 of 5 stars	$7.82 +1.4%	$9.50 +21.5%	-27.3%	$70.46M	$120.77M	N/A	330	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. THAR, GANX, FRMM, ATRA, and SPRO

How does NeuroSense Therapeutics compare to Tharimmune?

Summary

How does NeuroSense Therapeutics compare to Gain Therapeutics?

Summary

How does NeuroSense Therapeutics compare to Forum Markets?

Summary

How does NeuroSense Therapeutics compare to Atara Biotherapeutics?

Summary

How does NeuroSense Therapeutics compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. THAR, GANX, FRMM, ATRA, and SPRO

How does NeuroSense Therapeutics compare to Tharimmune?

Which has more risk and volatility, NRSN or THAR?

Do insiders & institutionals believe in NRSN or THAR?

Which has preferable earnings & valuation, NRSN or THAR?

Does the media favor NRSN or THAR?

Do analysts prefer NRSN or THAR?

Is NRSN or THAR more profitable?

Summary

How does NeuroSense Therapeutics compare to Gain Therapeutics?

Which has more volatility and risk, NRSN or GANX?

Do insiders and institutionals believe in NRSN or GANX?

Do analysts prefer NRSN or GANX?

Does the media favor NRSN or GANX?

Which has stronger valuation & earnings, NRSN or GANX?

Is NRSN or GANX more profitable?

Summary

How does NeuroSense Therapeutics compare to Forum Markets?

Do insiders and institutionals have more ownership in NRSN or FRMM?

Does the media favor NRSN or FRMM?

Which has more volatility & risk, NRSN or FRMM?

Is NRSN or FRMM more profitable?

Which has higher earnings & valuation, NRSN or FRMM?

Do analysts recommend NRSN or FRMM?

Summary

How does NeuroSense Therapeutics compare to Atara Biotherapeutics?

Does the media refer more to NRSN or ATRA?

Which has preferable valuation and earnings, NRSN or ATRA?

Do insiders & institutionals hold more shares of NRSN or ATRA?

Is NRSN or ATRA more profitable?

Which has more risk & volatility, NRSN or ATRA?

Do analysts rate NRSN or ATRA?

Summary

How does NeuroSense Therapeutics compare to Spero Therapeutics?

Do insiders and institutionals have more ownership in NRSN or SPRO?

Which has preferable valuation & earnings, NRSN or SPRO?

Is NRSN or SPRO more profitable?

Which has more risk & volatility, NRSN or SPRO?

Does the media prefer NRSN or SPRO?

Do analysts prefer NRSN or SPRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools